Search International and National Patent Collections
|1. (WO2018108106) ANTI-CD19 HUMANIZED ANTIBODY AND IMMUNE EFFECTOR CELL TARGETING CD19|
|Applicants:||CARSGEN THERAPEUTICS, LTD
SHANGHAI CANCER INSTITUTE
|Title:||ANTI-CD19 HUMANIZED ANTIBODY AND IMMUNE EFFECTOR CELL TARGETING CD19|
Disclosed are an anti-CD19 humanized antibody prepared from a murine monoclonal antibody, a chimeric antigen receptor containing the humanized antibody, and an immune cell expressing the humanized antibody. Not only does the humanized antibody of the present invention not produce an anti-antibody response (AAR) and a human anti-mouse antibody response (HAMA), but same also has better affinity than a murine antibody, and has excellent activity and safety, thereby providing a new means for treating CD19-expressing tumors.